592 related articles for article (PubMed ID: 8633143)
1. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
[TBL] [Abstract][Full Text] [Related]
2. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
[TBL] [Abstract][Full Text] [Related]
4. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
[TBL] [Abstract][Full Text] [Related]
7. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.
Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE
Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130
[TBL] [Abstract][Full Text] [Related]
8. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
9. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
10. [Oral contrast media for magnetic resonance tomography of the abdomen. III. Initial patient research with gadolinium-DTPA].
Claussen C; Kornmesser W; Laniado M; Kaminsky S; Hamm B; Felix R
Rofo; 1988 Jun; 148(6):683-9. PubMed ID: 2837806
[TBL] [Abstract][Full Text] [Related]
11. [The dynamic magnetic resonance study of focal liver lesions by FLASH sequences with bolus intravenous gadolinium-DTPA].
Olivetti L; Grazioli L; Maroldi R; Matricardi L; Milanesio L
Radiol Med; 1992 Apr; 83(4):353-60. PubMed ID: 1318558
[TBL] [Abstract][Full Text] [Related]
12. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
14. Diffusion weighted imaging of liver lesions suspect for metastases: Apparent diffusion coefficient (ADC) values and lesion contrast are independent from Gd-EOB-DTPA administration.
Benndorf M; Schelhorn J; Dietzel M; Kaiser WA; Baltzer PA
Eur J Radiol; 2012 Aug; 81(8):e849-53. PubMed ID: 22575171
[TBL] [Abstract][Full Text] [Related]
15. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
17. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions.
Russell EJ; Schaible TF; Dillon W; Drayer B; LiPuma J; Mancuso A; Maravilla K; Goldstein HA
AJR Am J Roentgenol; 1989 Apr; 152(4):813-23. PubMed ID: 2646872
[TBL] [Abstract][Full Text] [Related]
18. Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid.
Brody JM; Schafer L; Tung GA; Breuer J; Shamsi K
J Magn Reson Imaging; 2005 Apr; 21(4):391-7. PubMed ID: 15778951
[TBL] [Abstract][Full Text] [Related]
19. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
[TBL] [Abstract][Full Text] [Related]
20. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
